BioPharma Reporter

MAY 21, 2024

Life science startup Limula has raised $6.8 million to take its solution for automating cell therapy manufacturing to the next stage of development.

Manufacturing 52

Manufacturing Gene Therapy Development Life Science 52

Drug Discovery World

JULY 11, 2022

David Lewandowski, Business Director of Cell & Gene Therapy at Azenta Life Sciences, explains how efficient sample management can help to work efficiently and bring therapies to market faster. It has been estimated that by 2025 the FDA will be approving 10 to 20 cell and gene therapy products per year 2.

Gene Therapy 52

Gene Therapy Gene Development Production 52

Cloudbyz

MAY 19, 2021

Introduction Cell and gene therapy is an upcoming wave of therapeutic innovation in the healthcare and life sciences industry and is being pragmatically accepted worldwide. The gene therapy market reported its first market approvals back in 2017 and the evolution has been extensive ever since.

Gene Therapy 52

Gene Therapy Gene Manufacturing Production 52

BioPharma Reporter

AUGUST 14, 2023

Teknova, a producer of life science reagents, has opened a new GMP-certified production facility which it claims will enable bioprocessing and gene therapy companies to get into the clinic faster.

Reagent 98

Reagent Gene Therapy Life Science Manufacturing 98

BioPharma Reporter

MARCH 22, 2022

Fujifilm Irvine Scientific, Inc, has announced the acquisition of Shenandoah Biotechnology, a company supplying recombinant proteins to the drug discovery, life science research, and cell and gene therapy markets.

Gene Therapy 98

Gene Therapy Life Science Protein Gene 98

BioPharma Reporter

JULY 3, 2023

Donaldson, a provider of filtration products and solutions, has acquired Univercells Technologies, a producer of biomanufacturing solutions for cell and gene therapy research, development, and commercial manufacturing, to broaden its life sciences reach.

Gene Therapy 97

Gene Therapy Life Science Gene Manufacturing 97

Drug Discovery World

FEBRUARY 12, 2024

“In the upcoming year, we will see the expansion of new, more complex markets and updated requirements from regulators. Ensuring sufficient and timely patient enrollment in a rapidly growing number of cell and gene therapy clinical trials is becoming a bottleneck to advancing potentially life-saving therapies.

Genome 139

Genome Genomics Life Science Gene Therapy 139

The Pharma Data

OCTOBER 26, 2020

The agreement covers the gene therapy program targeting OTOF (OTOF-GT), the gene encoding the otoferlin protein. Sensorion is currently advancing two preclinical gene therapy programs conducted under a broad multi-program research partnership with the Genetics and Physiology of Hearing Unit at Institut Pasteur (Paris).

Gene Therapy 52

Gene Therapy Gene Manufacturing Production 52

Drug Discovery World

FEBRUARY 19, 2024

Financial landscape In 2023, life science companies experienced a significant decrease in funding, particularly seed funding for early-stage drug development. This has been a real cause for concern for the industry, which is also facing growing competition in the investment market from big tech and AI.

Development 59

Development Gene Therapy Drugs Antibody 59

Drug Discovery World

MAY 6, 2024

Thanks to a prestigious academic legacy, Europe has long been a dominant region for life sciences. Europe is traditionally a life sciences powerhouse, with a strong tradition in pharmaceutical discovery. The oldest, still active pharmaceutical company worldwide, Merck, started life in 1668 in Darmstadt, Germany.

Drugs 59

Drugs Life Science Gene Editing Gene 59

XTalks

JUNE 12, 2023

Moreover, Lonza, a global manufacturing partner for the pharmaceutical, biotech and nutrition industries, announced that two cell and gene therapies manufactured at their Houston site got FDA approval in 2022. The Global Cell Therapy Market Continues to Expand The global cell therapy market , valued at $10.35

Manufacturing 95

Manufacturing Gene Therapy FDA Approval Gene 95

XTalks

AUGUST 3, 2023

While most post-marketing activities are typically oriented towards marketing, sales, and commercialization of the drug, pharmacovigilance is fundamentally patient-centric, focusing on the safety and efficacy of pharmaceutical products once they reach the market. How is this shift affecting your post-marketing work?

Regulation 97

Regulation Marketing Life Science Drugs 97

ACRP blog

APRIL 5, 2023

The life sciences sector is increasingly leveraging technology across its operations, and this trend will continue in 2023 with more collaborations and partnerships between pharmaceutical, biotechnology, and medical device companies and information technology vendors, Lyons adds.

Big Data 52

Big Data Clinical Trials Clinical Trials Life Science 52

XTalks

MARCH 28, 2024

Headquartered in Milan, Italy, Italfarmaco is a privately owned global pharma company that has been making moves to bolster its presence in the US market through the formation of a new fully owned subsidiary, ITF Therapeutics LLC. As one of the most expensive therapies in the world priced at $3.2 million last year, of which $131.3

FDA Approval 105

FDA Approval Genetics Gene Therapy Gene 105

XTalks

MARCH 13, 2024

Related: Transforming Eye Care: Innovating New Glaucoma and Dry Eye Disease Treatments — Featuring Pierre Simon, VP Marketing, Sight Sciences – Xtalks Life Science Podcast Ep. There are also studies examining gene therapy-based techniques to repair or replace genetic defects contributing to this disease.

Gene Therapy 111

Gene Therapy Gene Life Science DNA 111

The Pharma Data

JANUARY 27, 2021

FDA Also Grants Two Orphan Drug Designations for the Company’s Gene Therapy Programs for Gaucher Disease and Mucolipidosis –. In addition, the FDA granted two orphan drug designations (ODDs) for its gene therapy programs for Gaucher disease and mucolipidosis. Currently, there are no cures for any of these disorders.

Gene Therapy 40

Gene Therapy Gene Protein Life Science 40

pharmaphorum

NOVEMBER 23, 2022

Innovative offerings around market access. A director in life sciences consulting for EY, she works within the commercial space for such companies, as well as their clients. “My I’ve always worked as a consultant for pricing and access strategies for clients, helping them to get drugs to market and access patients.

Life Science 98

Life Science Marketing Medicine Production 98

Pharmaceutical Technology

JANUARY 31, 2023

The US omnibus bill passed in late December 2022 will give the agency greater powers to regulate accelerated approval drugs, while the Inflation Reduction Act’s lowering of drug prices will create an uncertain environment for drug developers, he said. It’s much needed. It’s a hot area.” trillion Consolidated Appropriations Act.

Drugs 130

Drugs Regulation Gene Therapy Insulin 130

pharmaphorum

JANUARY 12, 2022

EMA “lags behind” other international regulators when it comes to approval timelines, finds EFPIA analysis. Only a regulatory framework that “embraces a culture of excellence and innovation” will make Europe a world leader in life sciences and ensure people can reap the benefits of life-changing new treatments.

Regulation 105

Regulation Medicine Marketing Gene Therapy 105

pharmaphorum

NOVEMBER 30, 2022

Veeva Systems invited pharmaphorum to attend its industry summit in Madrid this week, a huge event that gathered together over 1,000 individuals from life sciences and pharma. The question is, how can the journey there be accelerated, when on the horizon awaits a life sciences future very much immersed in speciality medicine?

Life Science 98

Life Science Pharma Companies Sales Marketing 98

XTalks

OCTOBER 18, 2022

Read on to learn why life science and clinical research professionals are choosing a career with Medpace. Being a scientifically-driven and therapeutically aligned CRO, candidates can put their life-science backgrounds to work in a broad range of positions across a range of therapeutic and specialty areas. Nephrology.

Clinical Research 111

Clinical Research Research Clinical Trials Clinical Trials 111

Drug Discovery World

SEPTEMBER 16, 2022

W here globally is innovation occurring and what factors – industry, regulatory, and academia – are helping developers get their products to market? Here, DDW Editor Reece Armstrong explores the global hubs of innovation for cell and gene therapies. The UK stands as one of the key markets for cell and gene therapies.

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

XTalks

MARCH 25, 2021

Xtalks is proud to announce the launch of the Xtalks Life Science podcast. Subscribe to the Xtalks Life Science Podcast to never miss a new episode. Fresh Conversations About Life Science Topics. Diverse Voices for Lively Discussions. Sarah is also an experienced webinar moderator.

Life Science 105

Life Science HR Clinical Trials Clinical Trials 105

XTalks

NOVEMBER 10, 2023

cTTP is a very rare, inherited and life-threatening blood clotting disorder caused by a disease-causing mutation in the ADAMTS13 (A disintegrin and metalloproteinase with thrombospondin motifs 13) gene, which encodes the ADAMTS13 enzyme that regulates blood clotting by cleaving the von Willebrand factor (VWF) protease.

FDA Approval 59

FDA Approval Gene Therapy Gene Clinical Trials 59

The Pharma Data

JANUARY 7, 2021

Dr. Anne Prener has more than 25 years of leadership experience within life sciences companies, and currently serves as Chief Executive Officer of Imbria Inc. a gene therapy company focused on eye diseases. and as venture partner at SV Health Investors. Dr. Prener previously served as CEO of Freeline Ltd.

Gene Therapy 52

Gene Therapy Life Science Production Clinical Development 52

XTalks

AUGUST 22, 2022

Blueprint plans to submit a Supplemental New Drug Application to the US Food and Drug Administration (FDA) in Q4 2022, as well as a type II variation marketing authorization application to the European Medicines Agency (EMA) in 2023. Activating and inactivating KIT mutations result in increased mast cell signaling, leading to SM.

Medicine 98

Medicine Clinical Trials Clinical Trials Trials 98

Pharmaceutical Technology

FEBRUARY 3, 2023

With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more. 1] BioNews. Hemophilia News Today. link] [2] Tang Q, et al.

Genome 244

Genome Genomics Medicine Gene Therapy 244

pharmaphorum

JUNE 11, 2021

These trends combine to increase the pace of innovation and the precision of therapies. Leading academic research institutions and pharma/biopharma players exploring therapeutic areas such as immuno-oncology or cell and gene therapy no longer start ‘analogue only’ projects because of time and productivity shortcomings.

Clinical Trials 111

Clinical Trials Clinical Trials Trials Compliance 111

Drug Discovery World

JANUARY 26, 2023

Kadans Science Partner and Canary Wharf Group (CWG), London, are developing an innovation facility providing access to fully fitted laboratories and space for developing life science companies , following the announcement of a joint venture to establish a new UK Life Sciences cluster at Canary Wharf. Why London?

Life Science 52

Life Science Scientist Development Gene Therapy 52

pharmaphorum

JULY 4, 2022

Together, the webinar panellists explored the potential of medical informatics solutions and methods in rare disease research, studies, data optimisation, and usability to overcome these challenges, all whilst maintaining compliance with data protection regulations and a patient-centric approach.

Genome 105

Genome Genomics Research Medicine 105

XTalks

FEBRUARY 6, 2024

Fractyl Health’s common stock commenced trading on the Nasdaq Global Market under the ticker symbol “GUTS” on February 2, 2024. Fractyl Health is actively developing two promising therapies for T2D treatment. ArriVent’s common stock started trading on the Nasdaq Global Market on January 26, 2024, under the ticker symbol “AVBP.”

Gene Therapy 98

Gene Therapy Gene Clinical Trials Clinical Trials 98

XTalks

FEBRUARY 27, 2024

Technologies like CRISPR-Cas9 have revolutionized the potential for gene editing, offering hope for curative treatments for conditions like Duchenne muscular dystrophy (DMD) and certain types of inherited blindness. Both therapies were awarded their approvals on the same day in December 2023.

Research 59

Research Drugs Gene Therapy Clinical Trials 59

Drug Discovery World

JANUARY 26, 2023

DDW Editor Reece Armstrong takes a look at the pharmaceutical research and development market in 2023 and asks key opinion leaders what challenges and trends will emerge throughout the year. billion showed the pharma giant taking further steps into the oncology market and developing its speciality medicines vaccines portfolio.

Development 98

Development Drugs Clinical Trials Clinical Trials 98

Drug Discovery World

AUGUST 10, 2022

By Mark White, Associate Director of Biopharma Product Marketing at Bio-Rad and Marwan Alsarraj, Biopharma Segment Manager, Digital Biology Group. Exactly three decades later, the first CAR T cell therapy hit the market. For example, it is challenging to regulate transgene copy numbers in each T cell, posing safety risks.

Manufacturing 98

Manufacturing Gene Genome Genomics 98

XTalks

MARCH 22, 2023

In October 2022, Xtalks celebrated two decades of bringing diverse stakeholders in the life science industry together through first holding physical events, then soon after, hosting exclusively online events. And drugmakers are using their R&D expenditure to justify setting astronomically high list prices for new therapies.

Life Science 97

Life Science Drugs FDA Approval Vaccination 97

Drug Discovery World

MAY 9, 2024

The challenge is to work with regulators, clinicians and patients to define the appropriate pathway to a safe and effective drug approval. Our vision is that the availability of an effective concussion therapy will make patients suffering long term debilitating symptoms a thing of the past. Rest Is not Enough!

Development 72

Development Hormones Drugs Trials 72

XTalks

AUGUST 2, 2023

Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. 2022 Revenue: Pfizer reported an annual revenue of $100.33 Pfizer Inc.

Sales 98

Sales Manufacturing FDA Approval Life Science 98